Participants sought for study investigating the possible preventative treatment of episodic migraine
What is the purpose of the study?
investigating the possible preventative treatment of episodic migraine.
Who can take part?
- Have a medical history of first symptoms of migraine at the age of 50 or prior
- Have a documented history of episodic migraine for at least 12 months
- Have been unsuccessful with or unable to take other oral medications for the prevention of migraine.
What will the study involve?
If you choose to participate, and the study is right for you, the study is up to 18 weeks.
The study is divided into a screening period and a treatment period. The treatment period starts with a placebo-controlled section where you will be randomised (shuffled) into an active or dummy treatment. The placebo-controlled phase will last 12 weeks, and you might be eligible for the open label extension phase (additional 12-weeks) where all subjects receive 75mg Rimegepant every other day. Neither you nor the study doctor will know which product you are receiving. This then is followed by one visit during a two-week follow up period.
You will also be asked to keep a headache diary during the 12 week placebo-controlled phase.
How to take part
If you would like to take part in the study or if you have any questions, please contact headache-research@kcl.ac.uk.
Added: 18 November 2024 | Deadline: 15 April 2025
